secwatch.observer — SEC 8-K summary
======================================

Issuer:     Climb Bio, Inc. (CLYM)
CIK:        0001768446
Form:       8-K
Filed at:   2024-08-27T23:59:59+00:00
Accession:  0001193125-24-207854
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eliem Therapeutics CSO departs, CFO role changed, Executive Chairman resigns amid strategic pivot
--------------------------------------------------------------------------------

- Valerie Morisset, EVP R&D and CSO, separated August 23; settlement provides 18 months base salary, pro rata bonus, accelerated equity vesting.
- Company shifts focus to autoimmune-driven inflammatory diseases (budoprutug) and ceases UK operations.
- Brett Kaplan appointed principal financial officer after Andrew Levin resigns as Executive Chairman; Levin remains Chairman.
- Levin continues as director and Chairman of Board; Kaplan's COO role unchanged.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1768446/000119312524207854/0001193125-24-207854-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1768446/000119312524207854/d884075d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-207854

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer